POPULARITY
12 episodes with Schrag
4 episodes with Schrag
2 episodes with Schrag
2 episodes with Schrag
2 episodes with Schrag
2 episodes with Schrag
2 episodes with Schrag
4 episodes with Schrag
2 episodes with Schrag
Charles Piller, investigative journalist for Science magazine and author of The Fail-Safe Society (1991) and Gene Wars (1998), discusses his latest book Doctored: Fraud, Arrogance and Tragedy in the Quest to Cure Alzheimers (2025). Historicising Alzheimer's research, Piller Piller situates how whistleblower, Vanderbilt professor Matthew Schrag, exposed a massive scandal involving a University of Minnesota lab led by a precocious young scientist (Sylvain Lesné) and a renowned director (Karen Ashe). Examining ego, professional aspirations together with the demands set upon researchers, Piller exposes how falsified data was at the heart of the leading hypothesis about the disease. Piller exposes Schrag's findings and this stunned not only the field of Alzheimer's research, but the ripple effects this discovery had on research institution, the pharmaceutical industry, universities and the public. With the “amyloid hypothesis” now set within a web of scientific deceit, Piller elaborates how this hypothesis allowed a cause and effect, “an injection of hope and belief” whereby targetting these proteins became the dominanting thinking in the field for combatting Alzheimer's disease. With the manipulation of data in plain sight, however, this necessarily put the future of Alzeiheimer's research at risk where research diverging from amyloid focus had been side-lined or even actively deterred all in order to ensure the primacy of the amyloid hypothesis, which Piller terms the “amyloid mafia.” Get full access to Savage Minds at savageminds.substack.com/subscribe
Matthew Schrag, the Alzheimer's whistleblower who uncovered one of the biggest medical deceptions in history, joins the show. Plus, Chuck Schumer takes the hits, absorbs the pain, and spares Democrats from a brutal shutdown battle—sometimes being a punching bag is part of the job. Produced by Corey Wara Email us at thegist@mikepesca.com To advertise on the show, contact sales@advertisecast.com or visit https://advertising.libsyn.com/TheGist Subscribe to The Gist: https://subscribe.mikepesca.com/ Subscribe to The Gist Youtube Page: https://www.youtube.com/channel/UC4_bh0wHgk2YfpKf4rg40_g Subscribe to The Gist Instagram Page: GIST INSTAGRAM Follow Mikes Substack at: Pesca Profundities | Mike Pesca | Substack Learn more about your ad choices. Visit podcastchoices.com/adchoices
Award-winning investigative journalist Charles Piller joins us in San Francisco for an in-depth look at what he says is a world of fraud, corruption, deceit, and greed that have set back important work on treating Alzheimer's disease. Nearly seven million Americans live with Alzheimer's, a tragedy that is projected to grow into a $1 trillion crisis by 2050. While families suffer and promises of pharmaceutical breakthroughs keep coming up short, investigative journalist Piller says that we've quite likely been walking the wrong path to finding a cure all along—led astray by a cabal of self-interested researchers, government accomplices, and corporate greed. Drawing on the work in his new book Doctored, Piller highlights a whistleblower—Vanderbilt professor Matthew Schrag—whose work exposed a massive scandal. Schrag alleged that a university lab led by a precocious young scientist and a Nobel Prize–rumored director delivered apparently falsified data at the heart of the leading hypothesis about the disease. From there, based on years of investigative reporting, Piller says he's exposed a vast network of deceit and its players, all the way up to the FDA. He points to evidence that hundreds of important Alzheimer's research papers are based on false data. In the process, he says even against a flood of money and influence, a determined cadre of scientific renegades have fought back to challenge the field's institutional powers in service to science and the tens of thousands of patients who have been drawn into trials to test dubious drugs. Learn more about your ad choices. Visit megaphone.fm/adchoices
Im letzten Blue Moon des Jahres wollten wir eure High- und Lowlights 2024 hören und schon mal auf das kommende Jahr 2025 vorgucken: Was war legendär und was unterirdisch für euch in den vergangenen 12 Monaten? Worauf freut ihr euch und was macht euch Sorgen im kommenden Jahr? Habt ihr was zum ersten oder letzten Mal gemacht? Ihr habt von beginnenden Therapien erzählt und dem Verlust treuer tierischer Begleiter.
Send us a text*DISCUSSION TOPICS*AJ's photo reveal at Lululemon Greenwich!TCS New York City Marathon! Who's running? Who's cheering?They're selling Peloton's at Costco???Peloton earnings call! Are they on the comeback?Alex Breanne Corporation update!Potential Peloton virtual cycling game! Thoughts?Jenn Sherman on tour! Anyone going?Halloween Peloton classes!Who still doesn't know who Shalimar is?Class Recommendations!
Ursina Ingold im Gespräch mit Lucie Schrag.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.CVS is laying off 2,900 employees as part of a cost-cutting plan and potential business breakup. Humana's Medicare Advantage star ratings have dropped significantly, impacting profits. Healthcare workers face burnout, while the payer-provider relationship is evolving. Mission Hospital in North Carolina is struggling after Hurricane Helene, and Steward CEO Ralph de la Torre is being sued by senators. Healthcare companies are urged to prioritize patient-centric experiences. The text also highlights upcoming healthcare conferences, telehealth trends, and insights into the relationship between providers and payers.The FDA has officially declared the end of the shortage of Zepbound and Mounjaro, putting pressure on companies selling compounded alternatives. Biopharma conferences in 2025 are important for showcasing clinical trial results. The FDA is set to make several key decisions in the fourth quarter, including approving a rival to a popular Pfizer heart drug. Roche plans to address an $8 billion sales gap due to biosimilar competition. Lilly is investing $4.5 billion in a "foundry" for advanced drug manufacturing. Additionally, there are resources available on topics such as AI in clinical research, genetic screening, gene therapy, and biosimilars. Other industry news includes potential sales of pharma units by Chinese company Wuxi, and the US's commitment to African manufacturing in HIV programs.Sanofi has sold the global rights to a rare autoimmune drug for cold agglutinin disease to Recordati in a potential $1 billion deal. Recordati will make an upfront payment of $825 million to Sanofi, with milestone payments of up to $250 million. Meanwhile, Novo's lowest dose of Wegovy remains on the FDA's drug shortage list. AbbVie has trimmed its full-year earnings guidance due to R&D milestone costs, following the success of its Parkinson's disease candidate Tavapadon. Relay Therapeutics is laying off 10% of its workforce to streamline its research organization. The pharma industry is prioritizing scaling GLP-1 manufacturing capacity to meet the demand for weight loss drugs. Lilly has ended its obesity drug shortage, while Novo continues to face shortages. WBL's proprietary library prep for cfDNA whole genome sequencing aims to enhance specificity, sensitivity, and data quality at low concentrations. In other news, BMS has received FDA approval for an Opdivo regimen in NSCLC and Bavarian Nordic's MPox shot shows antibody responses wane after 6 to 12 months.Dr. Matthew Schrag, a vascular neurologist at Vanderbilt University, is not prescribing the new Alzheimer's disease treatments, Kisunla and Leqembi, due to concerns over risks and costs. Schrag has a history of challenging prevailing science in Alzheimer's and has exposed instances of potential misconduct by researchers. In 2021, he raised allegations of data manipulation against Cassava Sciences, leading to ongoing scrutiny and calls for their phase 3 trials to be stopped. Despite distancing himself from the controversy, Schrag's findings have had a significant impact on the company. The article also discusses Roivant's unique approach to drug development, the latest advances in oncology research, and the challenges in navigating the path from preclinical studies to regulatory approval for gene therapies. The text highlights the importance of efficient therapeutic development processes and increasing diversity in clinical trials. Additionally, it provides links to resources on selecting clinical trial sites, unlocking partnerships for small biotech firms, and optimizing AAV manufacturing processes. The newsletter also includes updates on Medicare drug price talks, a groundbreaking trial for lung cancer treatment, and a map of a fruit fly's brain that has impressed neuroscientists.
In this episode, we discuss review boards for research with human subjects. Are they necessary? Are they efficient? Are scientists well equipped to make judgements about ethics? And are economists more ethical than psychologists? Shownotes Whitney, S. N. (2015). Balanced ethics review: A guide for institutional review board members. Springer. Schrag, Z. M. (2010). Ethical imperialism: Institutional review boards and the social sciences, 1965–2009. JHU Press. Kinsey ReportsMasters & Johnson How Institutional Review Boards can be (and are) Weaponized Against Academic Freedom Weaponizing the IRB 2.0 Psychologists' Involvement in Torture and the APA. Psychology Today.
Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain delve into the world of locally advanced rectal cancer, focusing on the latest treatment strategies and advancements in the field. Joined by esteemed guests Dr. Deborah Schrag, a medical oncologist from Memorial Sloan Kettering Cancer Center, and Dr. Krishan Jethwa, a radiation oncologist from the Mayo Clinic, the discussion centers around the groundbreaking Prospect study. This study challenges the traditional approach to rectal cancer treatment, emphasizing the importance of balancing therapeutic efficacy with minimizing chronic side effects. The conversation covers a range of topics, from the utilization of different chemotherapy regimens to the evolving paradigm of radiation therapy. Dr. Schrag and Dr. Jethwa provide valuable insights into determining the optimal treatment course for patients with locally advanced rectal cancer, including the selective omission of surgery and the significance of MSI high status in treatment decisions. Tune in to learn about the latest advancements in rectal cancer treatment, the implications of the Prospect study, and the importance of personalized, multidisciplinary approaches in oncology care. Don't miss out on this informative discussion that sheds light on the complexities of managing rectal cancer and the evolving treatment landscape. Stay informed and up-to-date with the Oncology Brothers podcast as they continue to explore the dynamic world of oncology treatment. Subscribe now and join the conversation! Guests: Dr. Deborah Schrag, Medical Oncologist, Memorial Sloan Kettering Cancer Center Dr. Krishan Jethwa, Radiation Oncologist, Mayo Clinic
The Will To Change: Uncovering True Stories of Diversity & Inclusion
In this episode, Jennifer speaks with Laura Alvarez Schrag, Senior Consultant at JBC, about making personal connections to foster belonging in organizations. They discuss Laura's background, the importance of sharing personal stories and being vulnerable, generational differences in connecting, and how leaders can role model embracing learning and change. Laura emphasizes that while technology enables some connections, human relationships are still essential, so leaders should focus on elevating individuals, which then lifts entire organizations. Discover how intimate work that starts with personal transformation can then radiate out to create cultures of belonging over generations.
Im letzten Blue Moon vor Weihnachten will Christoph Schrag wissen: Wie geht's euch mit Blick auf die kommenden Tage? Seid ihr im Team "Weihnachtself" und es könnte euch gar nicht besser gehen oder gehört ihr zum Team "Grinch" und hofft, dass alles bald vorbei ist? Wie verbringt ihr die nächsten Tage und wer ist um euch? Feiert ihr Weihnachten überhaupt? Heute ist viel Platz für Feier- oder Fürchterliches im Blue Moon mit Christoph Schrag.
Ben Schrag of the National Science Foundation talks about deeptech and how the government helps advance innovation. OUTLINE: (00:00) Introduction (00:56) Ben's career path (02:39) NSF's mandate regarding commercialization of scientific invention (04:39) SBIR and STTR programs (06:31) Origin of SBIR/STTR (08:33) Inventions that SBIR/STTR programs funded (09:55) Disruption (11:00) Statistics and criteria (13:25) How decisions about funding are made (15:10) Successful companies that NSF funded (19:29) Successful chemical startups that NSF funded (22:22) Collaboration (23:50) Trends as seen from the front row seat to innovation
Welcome back to Country Tough with Brandy Von Holten. Today's guest is Logan Schrag, a Kansas cowboy that owns Diamond Springs Ranch. His facility offers guided trail rides, a massive treehouse that is more like a beautiful apartment for the weekend, an event venue, and something he calls the "Cowboy Experience". No horse, no problem. Logan Schrag and Michael W. Green also do business consulting. Check him out www.cowboyexperienceks.com
Happy to connect with a pelo friend of so many of mine! We all are a family and on the same team! Enjoy! *Pelotalk is not affiliated with Peloton
Zachary M. Schrag's The Fires of Philadelphia: Citizen-Soldiers, Nativists, and the 1844 Riots Over the Soul of a Nation (Pegasus, 2021) is a gripping and masterful account of the moment one of America's founding cities turned on itself, giving the nation a preview of the Civil War to come. In 1844, Philadelphia was set aflame by a group of Protestant ideologues—avowed nativists—who were seeking social and political power rallied by charisma and fear of the immigrant menace. For these men, it was Irish Catholics they claimed would upend morality and murder their neighbors, steal their jobs, and overturn democracy. The nativists burned Catholic churches, chased and beat people through the streets, and exchanged shots with a militia seeking to reinstate order. In the aftermath, the public debated both the militia's use of force and the actions of the mob. Some of the most prominent nativists continued their rise to political power for a time, even reaching Congress, but they did not attempt to stoke mob violence again. At a time many envision America in flames, The Fires of Philadelphia shows us a city—one that embodies the founding of our country—that descended into open warfare and found its way out again. Zachary M. Schrag is professor of history at George Mason University. Caleb Zakarin is the Assistant Editor of the New Books Network. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network
Zachary M. Schrag's The Fires of Philadelphia: Citizen-Soldiers, Nativists, and the 1844 Riots Over the Soul of a Nation (Pegasus, 2021) is a gripping and masterful account of the moment one of America's founding cities turned on itself, giving the nation a preview of the Civil War to come. In 1844, Philadelphia was set aflame by a group of Protestant ideologues—avowed nativists—who were seeking social and political power rallied by charisma and fear of the immigrant menace. For these men, it was Irish Catholics they claimed would upend morality and murder their neighbors, steal their jobs, and overturn democracy. The nativists burned Catholic churches, chased and beat people through the streets, and exchanged shots with a militia seeking to reinstate order. In the aftermath, the public debated both the militia's use of force and the actions of the mob. Some of the most prominent nativists continued their rise to political power for a time, even reaching Congress, but they did not attempt to stoke mob violence again. At a time many envision America in flames, The Fires of Philadelphia shows us a city—one that embodies the founding of our country—that descended into open warfare and found its way out again. Zachary M. Schrag is professor of history at George Mason University. Caleb Zakarin is the Assistant Editor of the New Books Network. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history
Zachary M. Schrag's The Fires of Philadelphia: Citizen-Soldiers, Nativists, and the 1844 Riots Over the Soul of a Nation (Pegasus, 2021) is a gripping and masterful account of the moment one of America's founding cities turned on itself, giving the nation a preview of the Civil War to come. In 1844, Philadelphia was set aflame by a group of Protestant ideologues—avowed nativists—who were seeking social and political power rallied by charisma and fear of the immigrant menace. For these men, it was Irish Catholics they claimed would upend morality and murder their neighbors, steal their jobs, and overturn democracy. The nativists burned Catholic churches, chased and beat people through the streets, and exchanged shots with a militia seeking to reinstate order. In the aftermath, the public debated both the militia's use of force and the actions of the mob. Some of the most prominent nativists continued their rise to political power for a time, even reaching Congress, but they did not attempt to stoke mob violence again. At a time many envision America in flames, The Fires of Philadelphia shows us a city—one that embodies the founding of our country—that descended into open warfare and found its way out again. Zachary M. Schrag is professor of history at George Mason University. Caleb Zakarin is the Assistant Editor of the New Books Network. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/american-studies
Zachary M. Schrag's The Fires of Philadelphia: Citizen-Soldiers, Nativists, and the 1844 Riots Over the Soul of a Nation (Pegasus, 2021) is a gripping and masterful account of the moment one of America's founding cities turned on itself, giving the nation a preview of the Civil War to come. In 1844, Philadelphia was set aflame by a group of Protestant ideologues—avowed nativists—who were seeking social and political power rallied by charisma and fear of the immigrant menace. For these men, it was Irish Catholics they claimed would upend morality and murder their neighbors, steal their jobs, and overturn democracy. The nativists burned Catholic churches, chased and beat people through the streets, and exchanged shots with a militia seeking to reinstate order. In the aftermath, the public debated both the militia's use of force and the actions of the mob. Some of the most prominent nativists continued their rise to political power for a time, even reaching Congress, but they did not attempt to stoke mob violence again. At a time many envision America in flames, The Fires of Philadelphia shows us a city—one that embodies the founding of our country—that descended into open warfare and found its way out again. Zachary M. Schrag is professor of history at George Mason University. Caleb Zakarin is the Assistant Editor of the New Books Network. Learn more about your ad choices. Visit megaphone.fm/adchoices
Zachary M. Schrag's The Fires of Philadelphia: Citizen-Soldiers, Nativists, and the 1844 Riots Over the Soul of a Nation (Pegasus, 2021) is a gripping and masterful account of the moment one of America's founding cities turned on itself, giving the nation a preview of the Civil War to come. In 1844, Philadelphia was set aflame by a group of Protestant ideologues—avowed nativists—who were seeking social and political power rallied by charisma and fear of the immigrant menace. For these men, it was Irish Catholics they claimed would upend morality and murder their neighbors, steal their jobs, and overturn democracy. The nativists burned Catholic churches, chased and beat people through the streets, and exchanged shots with a militia seeking to reinstate order. In the aftermath, the public debated both the militia's use of force and the actions of the mob. Some of the most prominent nativists continued their rise to political power for a time, even reaching Congress, but they did not attempt to stoke mob violence again. At a time many envision America in flames, The Fires of Philadelphia shows us a city—one that embodies the founding of our country—that descended into open warfare and found its way out again. Zachary M. Schrag is professor of history at George Mason University. Caleb Zakarin is the Assistant Editor of the New Books Network. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/christian-studies
The essential handbook for doing historical research in the twenty-first century The Princeton Guide to Historical Research (Princeton UP, 2021) provides students, scholars, and professionals with the skills they need to practice the historian's craft in the digital age, while never losing sight of the fundamental values and techniques that have defined historical scholarship for centuries. Zachary Schrag begins by explaining how to ask good questions and then guides readers step-by-step through all phases of historical research, from narrowing a topic and locating sources to taking notes, crafting a narrative, and connecting one's work to existing scholarship. He shows how researchers extract knowledge from the widest range of sources, such as government documents, newspapers, unpublished manuscripts, images, interviews, and datasets. He demonstrates how to use archives and libraries, read sources critically, present claims supported by evidence, tell compelling stories, and much more. Featuring a wealth of examples that illustrate the methods used by seasoned experts, The Princeton Guide to Historical Research reveals that, however varied the subject matter and sources, historians share basic tools in the quest to understand people and the choices they made. Zachary M. Schrag is professor of history at George Mason University and the author of Ethical Imperialism and The Great Society Subway. His teaching website is historyprofessor.org. He lives in Arlington, Virginia. Twitter @zacharyschrag Caleb Zakarin is the Assistant Editor of the New Books Network (Twitter: @caleb_zakarin). Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network
The essential handbook for doing historical research in the twenty-first century The Princeton Guide to Historical Research (Princeton UP, 2021) provides students, scholars, and professionals with the skills they need to practice the historian's craft in the digital age, while never losing sight of the fundamental values and techniques that have defined historical scholarship for centuries. Zachary Schrag begins by explaining how to ask good questions and then guides readers step-by-step through all phases of historical research, from narrowing a topic and locating sources to taking notes, crafting a narrative, and connecting one's work to existing scholarship. He shows how researchers extract knowledge from the widest range of sources, such as government documents, newspapers, unpublished manuscripts, images, interviews, and datasets. He demonstrates how to use archives and libraries, read sources critically, present claims supported by evidence, tell compelling stories, and much more. Featuring a wealth of examples that illustrate the methods used by seasoned experts, The Princeton Guide to Historical Research reveals that, however varied the subject matter and sources, historians share basic tools in the quest to understand people and the choices they made. Zachary M. Schrag is professor of history at George Mason University and the author of Ethical Imperialism and The Great Society Subway. His teaching website is historyprofessor.org. He lives in Arlington, Virginia. Twitter @zacharyschrag Caleb Zakarin is the Assistant Editor of the New Books Network (Twitter: @caleb_zakarin). Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history
The essential handbook for doing historical research in the twenty-first century The Princeton Guide to Historical Research (Princeton UP, 2021) provides students, scholars, and professionals with the skills they need to practice the historian's craft in the digital age, while never losing sight of the fundamental values and techniques that have defined historical scholarship for centuries. Zachary Schrag begins by explaining how to ask good questions and then guides readers step-by-step through all phases of historical research, from narrowing a topic and locating sources to taking notes, crafting a narrative, and connecting one's work to existing scholarship. He shows how researchers extract knowledge from the widest range of sources, such as government documents, newspapers, unpublished manuscripts, images, interviews, and datasets. He demonstrates how to use archives and libraries, read sources critically, present claims supported by evidence, tell compelling stories, and much more. Featuring a wealth of examples that illustrate the methods used by seasoned experts, The Princeton Guide to Historical Research reveals that, however varied the subject matter and sources, historians share basic tools in the quest to understand people and the choices they made. Zachary M. Schrag is professor of history at George Mason University and the author of Ethical Imperialism and The Great Society Subway. His teaching website is historyprofessor.org. He lives in Arlington, Virginia. Twitter @zacharyschrag Caleb Zakarin is the Assistant Editor of the New Books Network (Twitter: @caleb_zakarin). Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/military-history
The essential handbook for doing historical research in the twenty-first century The Princeton Guide to Historical Research (Princeton UP, 2021) provides students, scholars, and professionals with the skills they need to practice the historian's craft in the digital age, while never losing sight of the fundamental values and techniques that have defined historical scholarship for centuries. Zachary Schrag begins by explaining how to ask good questions and then guides readers step-by-step through all phases of historical research, from narrowing a topic and locating sources to taking notes, crafting a narrative, and connecting one's work to existing scholarship. He shows how researchers extract knowledge from the widest range of sources, such as government documents, newspapers, unpublished manuscripts, images, interviews, and datasets. He demonstrates how to use archives and libraries, read sources critically, present claims supported by evidence, tell compelling stories, and much more. Featuring a wealth of examples that illustrate the methods used by seasoned experts, The Princeton Guide to Historical Research reveals that, however varied the subject matter and sources, historians share basic tools in the quest to understand people and the choices they made. Zachary M. Schrag is professor of history at George Mason University and the author of Ethical Imperialism and The Great Society Subway. His teaching website is historyprofessor.org. He lives in Arlington, Virginia. Twitter @zacharyschrag Caleb Zakarin is the Assistant Editor of the New Books Network (Twitter: @caleb_zakarin). Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/intellectual-history
The essential handbook for doing historical research in the twenty-first century The Princeton Guide to Historical Research (Princeton UP, 2021) provides students, scholars, and professionals with the skills they need to practice the historian's craft in the digital age, while never losing sight of the fundamental values and techniques that have defined historical scholarship for centuries. Zachary Schrag begins by explaining how to ask good questions and then guides readers step-by-step through all phases of historical research, from narrowing a topic and locating sources to taking notes, crafting a narrative, and connecting one's work to existing scholarship. He shows how researchers extract knowledge from the widest range of sources, such as government documents, newspapers, unpublished manuscripts, images, interviews, and datasets. He demonstrates how to use archives and libraries, read sources critically, present claims supported by evidence, tell compelling stories, and much more. Featuring a wealth of examples that illustrate the methods used by seasoned experts, The Princeton Guide to Historical Research reveals that, however varied the subject matter and sources, historians share basic tools in the quest to understand people and the choices they made. Zachary M. Schrag is professor of history at George Mason University and the author of Ethical Imperialism and The Great Society Subway. His teaching website is historyprofessor.org. He lives in Arlington, Virginia. Twitter @zacharyschrag Caleb Zakarin is the Assistant Editor of the New Books Network (Twitter: @caleb_zakarin). Learn more about your ad choices. Visit megaphone.fm/adchoices
The essential handbook for doing historical research in the twenty-first century The Princeton Guide to Historical Research (Princeton UP, 2021) provides students, scholars, and professionals with the skills they need to practice the historian's craft in the digital age, while never losing sight of the fundamental values and techniques that have defined historical scholarship for centuries. Zachary Schrag begins by explaining how to ask good questions and then guides readers step-by-step through all phases of historical research, from narrowing a topic and locating sources to taking notes, crafting a narrative, and connecting one's work to existing scholarship. He shows how researchers extract knowledge from the widest range of sources, such as government documents, newspapers, unpublished manuscripts, images, interviews, and datasets. He demonstrates how to use archives and libraries, read sources critically, present claims supported by evidence, tell compelling stories, and much more. Featuring a wealth of examples that illustrate the methods used by seasoned experts, The Princeton Guide to Historical Research reveals that, however varied the subject matter and sources, historians share basic tools in the quest to understand people and the choices they made. Zachary M. Schrag is professor of history at George Mason University and the author of Ethical Imperialism and The Great Society Subway. His teaching website is historyprofessor.org. He lives in Arlington, Virginia. Twitter @zacharyschrag Caleb Zakarin is the Assistant Editor of the New Books Network (Twitter: @caleb_zakarin). Learn more about your ad choices. Visit megaphone.fm/adchoices
The essential handbook for doing historical research in the twenty-first century The Princeton Guide to Historical Research (Princeton UP, 2021) provides students, scholars, and professionals with the skills they need to practice the historian's craft in the digital age, while never losing sight of the fundamental values and techniques that have defined historical scholarship for centuries. Zachary Schrag begins by explaining how to ask good questions and then guides readers step-by-step through all phases of historical research, from narrowing a topic and locating sources to taking notes, crafting a narrative, and connecting one's work to existing scholarship. He shows how researchers extract knowledge from the widest range of sources, such as government documents, newspapers, unpublished manuscripts, images, interviews, and datasets. He demonstrates how to use archives and libraries, read sources critically, present claims supported by evidence, tell compelling stories, and much more. Featuring a wealth of examples that illustrate the methods used by seasoned experts, The Princeton Guide to Historical Research reveals that, however varied the subject matter and sources, historians share basic tools in the quest to understand people and the choices they made. Zachary M. Schrag is professor of history at George Mason University and the author of Ethical Imperialism and The Great Society Subway. His teaching website is historyprofessor.org. He lives in Arlington, Virginia. Twitter @zacharyschrag Caleb Zakarin is the Assistant Editor of the New Books Network (Twitter: @caleb_zakarin).
The essential handbook for doing historical research in the twenty-first century The Princeton Guide to Historical Research (Princeton UP, 2021) provides students, scholars, and professionals with the skills they need to practice the historian's craft in the digital age, while never losing sight of the fundamental values and techniques that have defined historical scholarship for centuries. Zachary Schrag begins by explaining how to ask good questions and then guides readers step-by-step through all phases of historical research, from narrowing a topic and locating sources to taking notes, crafting a narrative, and connecting one's work to existing scholarship. He shows how researchers extract knowledge from the widest range of sources, such as government documents, newspapers, unpublished manuscripts, images, interviews, and datasets. He demonstrates how to use archives and libraries, read sources critically, present claims supported by evidence, tell compelling stories, and much more. Featuring a wealth of examples that illustrate the methods used by seasoned experts, The Princeton Guide to Historical Research reveals that, however varied the subject matter and sources, historians share basic tools in the quest to understand people and the choices they made. Zachary M. Schrag is professor of history at George Mason University and the author of Ethical Imperialism and The Great Society Subway. His teaching website is historyprofessor.org. He lives in Arlington, Virginia. Twitter @zacharyschrag Caleb Zakarin is the Assistant Editor of the New Books Network (Twitter: @caleb_zakarin). Learn more about your ad choices. Visit megaphone.fm/adchoices
The essential handbook for doing historical research in the twenty-first century The Princeton Guide to Historical Research (Princeton UP, 2021) provides students, scholars, and professionals with the skills they need to practice the historian's craft in the digital age, while never losing sight of the fundamental values and techniques that have defined historical scholarship for centuries. Zachary Schrag begins by explaining how to ask good questions and then guides readers step-by-step through all phases of historical research, from narrowing a topic and locating sources to taking notes, crafting a narrative, and connecting one's work to existing scholarship. He shows how researchers extract knowledge from the widest range of sources, such as government documents, newspapers, unpublished manuscripts, images, interviews, and datasets. He demonstrates how to use archives and libraries, read sources critically, present claims supported by evidence, tell compelling stories, and much more. Featuring a wealth of examples that illustrate the methods used by seasoned experts, The Princeton Guide to Historical Research reveals that, however varied the subject matter and sources, historians share basic tools in the quest to understand people and the choices they made. Zachary M. Schrag is professor of history at George Mason University and the author of Ethical Imperialism and The Great Society Subway. His teaching website is historyprofessor.org. He lives in Arlington, Virginia. Twitter @zacharyschrag Caleb Zakarin is the Assistant Editor of the New Books Network (Twitter: @caleb_zakarin). Learn more about your ad choices. Visit megaphone.fm/adchoices
Schrag & Schröder - Zwei altbekannte Radiogesichter. Zwei Stunden Zeit mit euch. Im Themensack: Aufreger, Zwiespälter und Rumspekulierer! Wie: der elende Krieg, die Energiekrise, das 49-Euro-Ticket, Shoppingwahn, Fahrradparkplätze - und Brasilien wird Weltmeister? Und alles, worüber ihr reden wolltet
My guest this week is Dr. Rebecca Schrag Hershberg, author of the excellent book for parents, The Tantrum Survival Guide (affiliate link). Rebecca shared some of her top tips for being a more effective parent, which starts with the simple recognition that we all struggle at times in our relationships with our kids. One of the biggest takeaways is about being present with our kids and finding ways to pause when emotions are high so that we can make better choices. (Which sounds a lot like what we try to help our kids with as parents!)
What happens when potential fraud is detected in research papers on major medical issues? In this episode, we talk to Charles Piller, an investigative journalist who published a shocking story in Science magazine in July this year laying out compelling evidence for misconduct in multiple journal articles on Alzheimer's disease. This misconduct appears to have occurred in recent papers involving the experimental drug, simulfilam, as well as older, foundational papers in Alzheimer's research. Charles's story focuses on the sleuthing of Matthew Schrag, a neuroscientist and physician at Vanderbilt University who studies Alzheimer's disease himself. In an extensive (even heroic) effort, Schrag identified over 100 potentially manipulated images in multiple major research papers. We talk with Charles about the consequences of those seemingly fraudulent images for the field and for public trust in science. We also talk about the potential consequences for whistleblowers like Schrag, and what journals and funding agencies are doing to support integrity in basic research. Cover art: Keating Shahmehri
Meygn Kelly takes a deep dive into Alzheimer's with Dr. Dale Bredesen, Dr. Matthew Schrag, and investigative journalist Charles Piller, to talk about the history of the disease, disturbing scientific findings regarding Alzheimer's drugs and treatments, how research that advanced certain hypotheses has been called into question, the revelation about falsified images, how scientists in question are attempting to explain what happened, the investigative journalism that exposed this story and brought the doctored images in the Alzheimer's research to the public, the lack of NIH action after the news came to light, how the NIH is involved in funding this questionable scientific research, what we know about the scientists in question, conflicts of interest in the scientific community, the era of mainstream medicine failing us, what's really the cause of Alzheimer's, how to help improve brain health and stave off Alzheimer's, memory tests we can do to help ourselves, and more.Follow The Megyn Kelly Show on all social platforms:YouTube: https://www.youtube.com/MegynKellyTwitter: http://Twitter.com/MegynKellyShowInstagram:http://Instagram.com/MegynKellyShowFacebook:http://Facebook.com/MegynKellyShow Find out more information at:https://www.devilmaycaremedia.com/megynkellyshow
Mt. Spokast! is a retrospective podcast celebrating the Alumni of Mt. Spokane High School's 2002 graduating class. On each episode, our host Brennon Poynor will sit down with classmates to see what they are up to now & wax nostalgic about the "good old days." This podcast helps support the Nick Wintersteen Memorial Scholarship. Which will award one graduating Mt. Spokasne senior with a scholarship of $2,500 to help pay for their further education and achieve their full potential in whatever they choose to pursue. Please visit the following link if you'd like to donate to the Nick Wintersteen Memorial Scholarship.
Waldbrände, Bahnchaos, kulturelle Aneignung, Benzinpreise, steigende Zinsen und die Frage: Können wir im Winter noch in die Sauna gehen oder wird alles abgeschaltet wegen Krise? Die Energiepreise treffen uns alle! Schrag und Schröder reden mit euch über alles, zwischen Weltpolitik und Wahnsinn.
With so many folks carrying cameras on the mountain or attempting to in this episode with Loren Schrag of Good Bull Outdoors we discuss what Loren and Ally run on the mountain filming, taking product or lifestyle photos and video and of course the infamous Good Bull elk captures. We talk some basic settings, audio, gear and a little post and the business Good Bull has evolved into over the years. Enjoy the episode! GET INVOLVED IN FIGHTING FOR OUR RIGHTS AS OUTDOORSMEN AND WOMEN BY SUPPORTING SPORTSMEN'S ALLIANCE, FOLLOW THE LINK BELOW: https://www.westerncontours.com/sportsmens-alliance Take an active roll in protecting our rights and privileges as hunters with HOWL For Wildlife: https://www.howlforwildlife.org Follow the links below for Western Contours partners, affiliates and discounts. www.westerncontours.com Western Fly Covers: When you spend as much time as we do outdoors you know how fast things can turn. Wet or damaged gear isn't going to keep you out there where you want to be. Ultralight element protection for your gear. use code Mainbeam10 of 10% off at www.westernflycovers.com Hartsky Signature Photography: use code: WESTERN15 https://www.hartskysignature.com/ Anxynt: https://www.anxynt.com?aff=5 Initial Ascent: https://www.initialascent.com?aff=5 Mountain Hunter Box: https://www.themountainhunterbox.com?via=guy Arrow Tech Archery use code: WESTERNCONTOUR www.arrowtecharchery.com Sasquatch Fuel: use code: Westerncontours https://sasquatchfuel.com/ Visit and subscribe to Western Contours on the Waypoint Collective https://waypointtv.com/western-contours Learn more about your ad choices. Visit megaphone.fm/adchoices
Hendrik und Christoph laden alle von euch ein, anzurufen, die gerade nicht in Deutschland sind. Ihr macht ein FSJ in Brasilien? Seid im Urlaub auf Malle? Seid ausgewandert in die Schweiz, habt einen Job in Australien oder reist gerade durch die USA? Dann seid ihr hier genau richtig. Wir wagen eine Reise um die Welt, mit euch! Wo auf diesem Planten steckt ihr gerade und wie ist es da so?
Monatlich wird unser Geld weniger wert. Das trifft vor allem die, die nichts mehr einsparen können, weil das Geld sowieso schon kaum reichte. Die Bundesregierung will jetzt mit Maßnahmen wie dem Neun-Euro-Ticket gegensteuern. Hendrik Schröder und Christoph Schrag haben euch gefragt, wo ihr die Inflation spürt, wie ihr damit umgeht, welche Maßnahmen ihr euch wünschen würdet und was zum Teufel dieses Neun-Euro-Ticket eigentlich bringen soll.
In the second of this two-part conversation Drs. Patrick Loehrer and David Johnson sit down with Dr. Deborah Schrag, the current Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center to continue the discussion of her roles as a leader, researcher, oncologist, public health expert, and more. If you liked this episode, please subscribe. Learn more at https://education.asco.org, or email us at education@asco.org. TRANSCRIPT Dr. Dave Johnson: Hi everyone, welcome back to Oncology, Etc. an ASCO educational podcast. My name is Dave Johnson. I'm at UT Southwestern Medical Center in Dallas. And I'm here with my good friend Dr. Pat Loehrer who serves as a director of Global Oncology and Health Equities at Indiana University. In the second half of our conversation with Dr. Deborah Schrag, the current chair of Medicine at Memorial Sloan Kettering Cancer Center in New York. In part one, we heard about Dr. Schrag's early life and background, as well as the importance of affordable cancer care and much more. Let's jump back into the conversation and hear about her current goals and initiatives at Memorial Sloan Kettering. I have a question for you. Jumping ahead a little bit. But I mean, you're such a role model for all of us. But you're now in a very powerful position as head of medicine at the preeminent cancer center in the world. So, I'd be interested in knowing what are your top initiatives? What did you come to this role wanting to do short-term and long-term? I'd be curious to hear from you about that. Dr. Deborah Schrag: Yeah. So, I have lots of specific initiatives, all the things that are probably very similar across medical cancer centers. We have to figure out the role of immuno-oncology. We have to figure out the role of CAR T-cell Therapy. There are lots of specific things, but let me tell you about three sort of overarching principles and things that I think we need to think about. So, one of the reasons why I decided to leave my job where I really focused on training researchers and building a research program to lead a department of medicine that has a mix of clinicians, educators, and investigators is that there's really a profound sense of exhaustion and disconnection. I'll use the word even burnout or people get the sense of losing the joy in the practice of medicine. And as corny as it sounds, and I know I'm going a little corny here, Dave. But I really want to help bring back and connect people to the joy in the practice of medicine. It's the joy that we experience when we crack a tough case, when we help a patient, when our patients make us laugh, when our patients and their families make us cry, when they drive us bananas, when they cook us food that is inedible, just reconnecting us to the joy, to the stories. I really wanted to try to be a different kind of leader because I felt that I could make a contribution to the field of academic medicine in general and oncology in particular, by working with faculty to set them up to tap into that joy, because I know they all started with it. I know they all went into medicine because they care about those human stories, because they do want to make a difference. This past week, a fellow intern of mine who you may know, passed away. His name was Paul Farmer. He was the head of Partners in Health and he was an infectious disease physician. There's a book about him by Tracy Kidder that's really moving. There's also a documentary about him called, Bending the Arc, which I would highly recommend. Paul was an incredible inspiration, just incredible, but he brought so much joy to the practice of medicine. I remember when Paul was going to some of the poorest places on the planet, specifically Cange, Haiti. He got an idea that he needed to bring chemotherapy because there were large cancers that were untreated. And he wanted to get leftover chemotherapy from the Dana-Farber. So, in the 1990s, when I was a fellow, he would ask me whether I could get him any leftover Taxol. I was like, ‘Paul, I can't do that. It's not safe. You can't take leftover Taxol to Cange'. And he said, ‘Deb, just wait, the drugs will be oral soon, and then I'll get it'. But guess what? Paul came back to me in 1999, and capecitabine had been approved. The oral equivalent of 5-FU. He held my feet to the fire. He said, ‘Every time you have a dead patient, if there's any leftover capecitabine, I want you to get it for me'. Inspirational leadership, connecting people to the joy in the practice of medicine. I would say that's number one. There's no one simple formula or way to do that. It's hard work. It requires a team I think a lot more teamwork into the practice of medicine. I think we're coming out of a hard two years where we've been confined to Zoom boxes. But it's a lot easier when we can sit together in a room and have a pizza and a beer on a Friday afternoon. But we have to figure this out, and we will, step by step. The other big thematic area, I think, has to do with the patient experience. Dave, I mean, when I started out as a fellow, patients with advanced lung cancer were living for 10 months, 10-12 months, that was a pretty good run with advanced metastatic non-small cell lung cancer. Well, these days, it's 2-3 years, and there's even quite a tale of patients who were living 4-5 years. And that is a long journey. It's no longer the 800-meter sprint, it's a half marathon, turning into a marathon and even an ultra-marathon. So, the way we deliver care needs to change. So, we're really rethinking here, how we deliver care. So, as an example of some, if you go back to the 80s and 90s, cancer chemotherapy was something that happened in the hospital. And in the last quarter century, we've transitioned that to an outpatient practice. I think in the next quarter century, we won't transition all of it, but we will transition a lot of it to home. As an example, I'm struck by when patients undergo IVF, they get handed some Lupron and are taught how to self-administer Lupron every day, so they can undergo a fertility cycle. But when those same women get breast cancer, they have to come into the clinic and sit and wait and take half a day off of work to get the same Lupron. The same is true for men with prostate cancer. Why is that? It's because of policies, and it's not safety, it's not patient-centered. So, I think we have an opportunity to change the patient experience. I think we'll be able to give immunotherapy at home, and HER-2 agents at home. We have to do the trials and make sure that it's safe, but we have to make cancer care more patient-centric and improve the experience. And that's just essential when it's a marathon that we're asking our patients to run, not these 12-month sprints. Families need this also. So, those are a few of the challenges that I want to take on. Joy in medicine, patient experience, and of course, the physician-scientist pathway needs to be strengthened. Dr. Pat Loehrer: I love it. You can imagine between Dave and me, I think that resonates so much about having joy in medicine. I've not heard other people talk about that, but I really think that's an important vocation. But I'm going to ask you something else too because, in the efforts of being joyful and being a role model for that, there's the other side of it, where you can't actually let your hair down, and really be depressed, if you will, or down because you can't let the other side see that. And so, who do you lean on if you will, your confessor that you can talk to when you're feeling down when you're trying to fight the anti-joy part of your job? Dr. Deborah Schrag: I have lots of friends outside of medicine. And I've always found that that's really helpful to make time for friends outside of medicine. They help connect me to humor and other things. I'm coming up on a big high school reunion. My high school classmates and I still meet for picnics in Central Park. And there are about 120 in our graduating class. And I think we'll have about 110 of us getting together. We still have picnics with 40-50 people attending. So, there's nothing like old friends from childhood who now do all kinds of different things. So, that's really helpful. But I've also found that my mentors and colleagues who trained me and who know me really well, are a great source of advice. So, leaders in academic medicine, and I've always found that I've been able to get advice from people who were senior and leaders, people such as Dr. Mayer, Dr. Benz, Dr. Jim Griffin, and also junior colleagues. I now increasingly as I get old, I rely more and more on my trainees and my mentees. So, some of the folks I know best are people who I trained. So, I'll just give you one example. Many of you may know Ethan Basch. We worked together when we were both just coming up. I was an assistant professor. He was a couple of years behind me. I mentored him. Well, he's now chief of the Division of Oncology at UNC. He and I have written lots of grants together. We're really partners now. But it's been a lifelong professional friendship. Sometimes when I just need to let my hair down, I get on the phone with Ethan, and yeah, there's a little bit of commiserating. But I'll give you an example that runs through Dave. Some really valuable experiences had to do with being asked to serve on committees. I think it's great. I just want to give a shout-out to ASCO. Some of my earliest professional relationships were with superstars that I met through ASCO. So, people like Joe Simone, reading his Simone's Maxims everyone needs to read Simone's Maxims if you haven't. There was a guy by the name of Christopher Desh, who sadly passed on. But he was an ASCO member who practiced at the Virginia Commonwealth University back in the late 1990s. Boy, did that guy understand the joy in medicine, some of the early folks who started QOPI. Being introduced to those individuals who practiced in different parts of the country and who had different kinds of challenges - having that sort of rich network has been incredible. At some point, I think through such a connection, maybe it was through Dr. Mayer, I was referred to Dr. Johnson, who was then running the American Board of Internal Medicine committee that wrote the oncology exam. I participated in that for a few years that was led by Dr. Johnson. And I met incredible people on that committee, including Dr. Johnson, just Dr. Johnson's stories could inspire anyone and get them back on track just in terms of the humor and the joy and the love, and really the pride in the profession. But I met Jamie Von Roenn that way, who's now leading educational efforts at ASCO, she was on that committee. Lynn Schuchter became a good friend of mine as a result of that. So, I would just say, sometimes you need to get out of your own space. And sometimes I need to get out of Dodge, as they say, I need to get out of New York, get out of Boston, and being connected to colleagues across the country has been so rewarding. I have a network of friends at other institutions who I rely on. Serving on external advisory boards is a great place to meet people. Study section, if anyone has the opportunity to be on study section. That's a fabulous opportunity. So, I think participating in peer review, showing up at meetings, serving on ASCO committees, or ASH or AACR. These are really important experiences. And I will say in my leadership role, I'm really trying to make it clear to faculty that I encourage them to take time to participate in these activities and attend these events and even travel because the traveling is important, too. I could not have gotten the same dose of Dave Johnson, if I had not actually gone to the meeting, spent all day writing board review questions, and then having a nice meal afterward. That was part of the experience. I don't know what you would say, Dave, but that was my view. Dr. Dave Johnson: So, one of the things that Osler talked about was the fellowship of the profession, and how important it is to have those relationships. Even if one can't physically be with that individual, developing that spiritual relationship is really critically important. I'm so glad you brought this up and expanded on it in the way you did because I think it's absolutely critical to retain the joy of medicine. It's our colleagues, as well as our patients that make it such a marvelous, majestic profession, in my view. Dr. Pat Loehrer: I was going to just add something if I could. So, Deb, replace me on the ABIM, just to let you know, because we had certain slots on there. One of the not sure if it was the rules or guidelines that were mandated is that everyone needed to take the oncology boards, even though we wrote the questions, we had to take the test. And you knew that and you had such unbridled enthusiasm for this. I still remember this deeply, and that not only did you recertify for the oncology board, but you also studied to take the medicine boards too. Your love of medicine is so contagious. And I'm sure everyone at Memorial benefits from this. Dr. Deborah Schrag: Thank you. That's very nice to say. I do, I love the stories. I've been rounding with the house staff on the inpatient service. I think both of you know, inpatient oncology, as we're able to do more and more in the outpatient setting, our inpatients are very, very sick. And we often get a front-row seat to what I would call the social determinants of health challenges. In other words, if you've got relatives and resources, you may be able to be at home. But if you have severe pain or symptoms, and you lack the relatives, or you live on a fifth floor, walk-up, or just don't have the resources to get the home care that you need, you're more likely to be in our hospital. But as I round with the house staff, I find myself asking them to tell me more about the patient stories. Because when I round and they tell me that it's a 74-year-old with peritoneal carcinomatosis, jaundice, and abdominal pain. I'm so old that I've seen so many hundreds of those patients and the management hasn't changed very much. But what's really the privilege is to understand the journeys that got people where they are, and to learn a little bit about who these people are. I try to do that when I round with house staff and I find that it makes the experience better for them. I have to say that I do worry about how we train young physicians in oncology because what they see on the inpatient side is really the hardest of the hard, that's obviously less true in a leukemia service, where they're delivering lots of curative therapy or a stem cell transplant service. But in solid tumor oncology, it's really hard. I think it's something we have to have to tackle. We have to rethink education and medical oncology. I'm hoping that we're going to do that. That's also on the bucket list, by the way. I think we have to do that as a profession. And I know both of you are passionate champions and advocates for education, as is ASCO. But I think it's really imperative that we do that if we are to keep attracting talent. And then I just want to make one more point, which is that New York City is one of the most diverse places in the United States. I don't know about the planet, because I don't know the whole planet. But in the United States, we are incredibly diverse. But the oncology workforce does not yet look like that. So, we have a lot of work to do to train a much more diverse workforce. We're doing well with respect to gender, very well. We're literally about 50/50, we may even have a little bit higher proportion of women on the faculty here at MSK. And I think that's true nationally as well. But with respect to Blacks and Hispanics, and other underrepresented communities, Native Americans, we've got a long way to go. And we have a pipeline problem. And that's going to be hard. But it's hard work that we have to do, and I know you guys are working on that in your own centers as well. Dr. Dave Johnson: Let me follow up on that. What attributes are you looking for in trainees and newly hired faculty? Whether they be junior or senior faculty? What are the characteristics or attributes you seek that you think predict, or certainly you want your individuals to possess? Dr. Deborah Schrag: We all want people who have everything, but I would say creativity, the willingness to take risks, and the ability to ask a question. I say this to the trainees, frankly, I say it to my own children as well. ‘It's okay, take a harder course. Yes, you may get a B minus by trying something new and different, that doesn't play to your strengths. But try something new. Take risks. Yes, the trial may fail. Yes, you may not get that grant.' But I think a willingness to take risks, a willingness to put yourself out there, a willingness to stretch. I'm also looking for people who can work in teams because there is no aspect of medical care that happens in MSK, I suspect that it's also true that maybe medicine in Antarctica, but even medicine in Antarctica is probably a team sport. Medicine has become a very complicated team sport. It's a very complicated dance with pharmacists, nurses, and APPs. It takes a village to give a course of immunotherapy. It is very complicated. And so, when people like to control things and like to do everything themselves, they're going to have a hard time. And that's true I find for teaching, laboratory investigation, wet lab, dry lab, most good, impactful, important science in oncology these days, clinical trials, wet, dry, all of it gets done in teams. Teams that have people with different levels of training, different skill sets, early stage, late stage, people who are quantitative, people who can write, people who can program, people who can do lab experiments, and people who know what an organoid is. People who know how to program an in R. All different kinds of skill sets but they have to be able to work in teams. People who can't do that are going to struggle to achieve maximum impact. I'm not saying that there isn't room at the end for the occasional genius person who likes to work solo. But that's not really what we need to move the needle. So, I need team players. I think there is a big emphasis on collegiality. Of course, we want smart and we want brilliance. But sometimes a drop less brilliance and a drop more collegiality and being able to work together in a team, it goes a long way and it's the difference between doing something impactful and not. That's what I look for. I also think that it takes all different kinds of people. And no one has to excel at everything, but it's great for people to be able to excel at something. So, passion, drive, and ability to ask questions, and not being afraid to occasionally fail and having some tolerance for that and trying to make sure that leaders are able to tolerate that, too. We have to be able to. Dr. Dave Johnson: Yeah, I think those are great suggestions. We're getting near the end of our time today, and we have a lot more questions to ask. But what's your biggest fear, as the head of the Department of Medicine, looking to the future, what causes you to lose sleep at night? Dr. Deborah Schrag: I think the business of medicine. If medicine turns into something that feels just like [inaudible] work, and losing physicians, if we don't respect physicians' need to take care of themselves, to take care of their families, and yeah, to find that joy, then we will not attract the top talents. I think we need great minds and great hearts and people from all walks of life to enter the profession, because that's the talent that we need, to quote my friend, Paul Farmer, ‘Bend the arc'. And you know, we need to bend Kaplan-Meier curves in the right direction. And we need the talent to come into the profession, and if they see that we are not happy and not thriving, the next generation is going to go elsewhere. I don't want to begrudge my wonderful endocrinology colleagues. We need people to tackle diabetes, and we need great surgeons and great anesthesiologists, too. So, it's not just oncology. In medicine, I'm responsible for all kinds of discipline. And boy, we need a lot of cardio-oncologists because we've created all kinds of new challenges. So, it's all of the sub-disciplines of medicine, but I think physician well-being and attracting talent to the field is really essential and making sure that the business side of medicine doesn't take over and destroy the core promise and premise of academic medicine. It is a spectacular profession and calling, and it has led to so many advances that have really changed the world. And we have to, I think, preserve the good in that. My fear is that that gets further eroded. Dr. Pat Loehrer: Just one last question from me. Thank you for all your wonderful comments. But I think I have to ask this because it's such an unusual thing as they brought up at the beginning that you're the first female Head of Medicine at Memorial and Lisa DeAngelis is the first Physician in Chief. And so, although there is gender equity in medicine, there is not gender equity and leadership around the academic world. And this is a very unique situation there. Can you reflect a little bit about the significance of this and perhaps, lessons learned, particularly if you're speaking to a younger version of yourself or a young woman who's thinking about a career? What are the lessons between you and Dr. DeAngelis mean? Dr. Deborah Schrag: I'm not sure I've been at it long enough to have lessons. I'm just so grateful. So, I'm not in the generation that was a trailblazer. I'm a beneficiary. So, I've had the privilege of being trained by Dr. Jane Weeks, by Dr. Judy Garber. I, myself, had so many great mentors who were women. I would say to women, that you can have it all. You just may not be able to have it all at once. Women and men have to make choices. Can you have a lab and be a laboratory investigator? Yes. Can you do that and have a family? Yes. I think running a high-power lab and having a gigantic clinical practice and running clinical trials, I think the three-legged stool and the so-called triple threat is really, really hard. But I think it's hard for women and men. What I would also say to women is you don't have to be the boys - be yourself. I think the best advice I can give to leaders is to be authentic. Because everyone, men, women, people smell a phony and no one likes to phony. So, I think if you know how to partner, you understand that it's a team sport. I think women do that really well. So, I think being authentic, and I think women need to hear that, you don't have to emulate male role models. You have to be yourself. I would love to emulate the two of you. I have to thank both of you because the Indiana Miracle and Dave from his Vanderbilt days, Vandy, as Dave likes to call it, from his Vanderbilt days to his Texas days, like, the two of you are such incredible thought leaders and inspirational leaders in oncology, but I can't be you. The best we can be is sort of the best version of ourselves but we can be inspired by the great qualities that we see in other leaders and carry a little bit of that with us. So, I think that goes for women and for men. Dr. Pat Loehrer: Thank you! Well said, and I appreciate the thoughts. We've kind of gone through this and we're going to have to wrap it up. One of the questions that we often times ask our visitors is if there's a book that they're reading, a documentary that they're watching, a movie they're seeing, or anything you'd recommend? Dr. Deborah Schrag: That's a good question. So, yes, actually. One of the ways that I learn about leadership that I find, actually a fun way that's both relaxing and educational, is to read a biography. I love reading biographies. I'm going to name two. And these are popular books - for scholars these may not be. First really fun book is ‘The Splendid and the Vile', by Erik Larson. It's a book about Winston Churchill in 1940, and how he has to try to persuade the United States to enter World War Two, but it's really about a particular year in history and Winston Churchill. Dr. Dave Johnson: It's a great book. Dr. Deborah Schrag: It's called, The Splendid and the Vile. I just learned so much about leadership from that book and the decisions that Winston Churchill makes in his bathtub. So, just read that book and think about what Winston Churchill does in his bathtub. I can't lead from my bathtub, I live in a New York City apartment, but that's one. Then more recently, I guess there's a little German theme happening here, is, The Chancellor. It's about the life of Angela Merkel. It's long, I haven't finished it yet. But it's incredible. What a story, East Germany, her leadership style, how she studies chemistry, how she rises. It's a fantastic book. It's called, The Chancellor. So, I will recommend that one. Then the last one, my beloved nephew who's like a son to me. He's about 36 years old, and he has ALS. And he's completely paralyzed. He is on a vent and he has two little kids. But he released a documentary that actually won at the Tribeca Film Festival called, Not Going Quietly, which is about a cross-country trip that he made. He's a pretty inspirational character, despite the fact that my nephew was completely locked in, he communicates only with his eyes. He is living a remarkable life. I think that documentay, I know this is a shameless plug for my nephew, but he's a pretty inspirational character. I don't necessarily agree with 100% of his policy prescriptions and recommendations. But there are lots of ways to make meaning in the world. So, that's another documentary. Dr. Pat Loehrer: That's incredible. Thank you so much for sharing that. I'm going to look it up. People think cancer is the worst thing you can get but there are worse diseases to have. Dr. Deborah Schrag: Yeah, I think this one might change your idea. And then I would also say Paul Farmer's Bending the Arc. I think for young physicians who haven't seen that movie, I would recommend Bending the Arc. Dr. Pat Loehrer: Thank you. Dr. Deborah Schrag: Thank you! It's been great to chat with you. Dr. Pat Loehrer: It's great. So, that's all the time we have for today. And I really want to thank you, Deb, for joining us and for all your insight. It's been wonderful. I also want to thank all our listeners for tuning in to Oncology, Etc. This is an ASCO Education podcast where we'll talk about just about anything and everything, if you've heard. If you have an idea for a topic or guest you'd like to see on the show or a host that you would like not to see on the show, just email us at education@asco.org. Thanks again. And Dave, I just have a riddle for you here. How do you make an octopus laugh? Dr. Dave Johnson: Show him your picture. Dr. Pat Loehrer: Ten-tickles. That's all we have for today. You guys have a good evening. Take care. Thank you for listening to the ASCO Education podcast. To stay up to date with the latest episodes, please click subscribe. Let us know what you think by leaving a review. For more information, visit the comprehensive education center at education.asco.org. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.
Bernie talks with Tim Schrag, the editor of the K-State Alumni Magazine, the K-Stater. See omnystudio.com/listener for privacy information.
In part one of a two-part conversation, Drs. Patrick Loehrer and David Johnson sit down with Dr. Deborah Schrag to discuss her roles as a leader, researcher, oncologist and public health expert. The current Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, Dr. Schrag discusses the joy and passion she has found throughout her career, and more. If you liked this episode, please subscribe. Learn more at https://education.asco.org, or email us at education@asco.org. TRANSCRIPT Dr. Pat Loehrer: I'm Pat Loehrer. I'm the Director of the Center of Global Oncology and Health Equity at Indiana University. Dr. David Johnson: Yes. And hello, I'm David Johnson. I'm at UT Southwestern in Dallas, Texas. Dr. Pat Loehrer: And welcome to another version of Oncology, Etc. Dr. David Johnson: Yeah, great guest today, before we get started with our guests, though, Pat, what are you reading these days? What can you recommend to me? Dr. Pat Loehrer: Well, I'm reading Jamie Raskin's book, which is about his son and about the insurrection. It's really a wonderful read so far, particularly I think about the family nature and how much he deeply respected his son who unfortunately committed suicide. Dr. David Johnson: Right before one of the impeachment trials as I recall, right? Dr. Pat Loehrer: It was right before the January 6 insurrection. Dr. David Johnson: Yeah, terrible situation. I have a book I've been meaning to recommend for a while. It's one that I've given to all the chief residents I've worked with over the last several years. And today's guests made me think about this book. It's entitled, Osler: Inspirations from a Great Physician. It's written by Charles Bryan, who's the former Chair of Medicine at the University of South Carolina in Columbia. Dr. Pat Loehrer: You trained with Osler, didn't you? Dr. David Johnson: I was a couple of years behind him. He was my senior resident. For anyone who's an Oslerphile, it's a great book to have. But even if you're not, it's got some wonderful lessons to be learned about how to interact with one's colleagues, and a lot of information about leadership, which is why it made me think of today's guest, Dr. Deborah Schrag who we're really excited to welcome to Oncology, Etc. Dr. Schrag is the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York. She's a highly accomplished healthcare leader, clinician-researcher, and expert in public health and population science. Deborah received her medical degree from Columbia University and completed her residency in internal medicine at Brigham and Women's. She obtained her medical oncology training at Dana-Farber in Boston and also received an MPH degree from the Harvard School of Public Health. After a brief stint on the faculty at DFCI and Brigham and Women's, she joined the division of gastrointestinal Oncology at Memorial Sloan Kettering, where she was an associate member and Associate Professor of Public Health and Medicine. In 2007, I believe it was, she returned to Dana-Farber and Brigham, where she continued her work focused on improving the delivery, quality, and effectiveness of cancer care. While there, she served as chief of the Division of Population Sciences until this past year when she returned to Memorial to chair the Department of Medicine. I also think she's the first woman to hold this position, but we'll learn about that momentarily. Deb is internationally recognized as a pioneer for her work engaging patients in reporting outcomes as a way to improve care. She has led pragmatic trials using informatics strategies to optimize patient and clinician wellbeing, efficiency and quality, and equity of care. In short, she's a true superstar, leading the department, the major department, in one of the world's foremost Cancer Institutes. Deb, welcome to Oncology, Etc. Thank you so much for accepting our invitation. This is a relatively new oncology podcast, but already, we're known for our incisive, deeply penetrating questions. So, I have a question for you to start off. Do you have any carpentry skills? Dr. Deborah Schrag: Absolutely none whatsoever, Dave. None. Dr. David Johnson: I'm disappointed. It's my understanding that Schrag is German for cross or a slant and people who build cross-legged tables. So, I was hoping, my house was destroyed recently, and I'm looking for replacement furniture, and I was hoping you might be able to help me. Dr. Deborah Schrag: I apologize. But I'm not going to be able to help. The name, you're correct, though, David, is a German name. So, my family does hail from Germany and they made malt, which is the major ingredient in beer. I'm not sure where the name comes from. But they ran malt factories and shipped malt all over to all the beer, before there were craft beer distilleries, that's what they did. Dr. Pat Loehrer: That may come in handy by the end of this podcast, by the way. Dr. Deborah Schrag: Could be. Dr. David Johnson: Well, speaking of your family, tell us a little bit about your background and where you were raised, and your family members. Dr. Deborah Schrag: Sure! I'm glad you asked that because I really have been very influenced by where I grew up. And as I think about it, experiences that go back to first grade got me where I am today. So, I am from New York City. I grew up in Manhattan in the 1970s. And as you may know, that was a pretty rough time in the history of New York, what's often referred to as the 'bad old days', although it didn't feel that way to me. But I started out attending New York City public schools. And at that time in my neighborhood on the Upper West Side of Manhattan, my first-grade class had about 45 students, and one teacher, there were about five or six of us who spoke English, and everyone else was a recent Puerto Rican immigrant. I pretty much sat in the corner and read to myself. Now I didn't stay in the public school system for long, but I saw in first grade, how things weren't fair. And I saw and felt my own privilege, acutely. And even as a little kid, I had that sense. Eventually, my parents transferred me to private school later on. And there were kids in the neighborhood who didn't have the same privileges that I did. But living in New York, you walk around, you're confronted with disparities every day. We still see it today with homelessness on the streets. At that time, there was a lot of alcoholism and the use of drugs. And they were two blocks north that were safe to walk and two blocks east that were not safe to walk. So, this really stuck with me from a very early age. As a student in summer jobs, I worked lots of interesting jobs. I started at 14 scooping ice cream at Baskin Robbins, I worked at a famous Deli in New York called Zabar's, selling coffee. Lots of interesting jobs that I worked during holidays and vacation times. But one of my first jobs was working in an organization called the Floating Hospital, which was a big old ferry boat that circumnavigated Manhattan, and it provided a summer camp. And we would take 1800 people on a boat around Manhattan every day. And my job was to do lead testing. And I learned how to stick kids, test them for lead because there were incredible amounts of lead poisoning in New York City in the early 1980s. And then we would work on tracing the kids and these were toddlers, two-year-old, three years old. There were many families who were living in homeless shelters in New York City in the early 1980s. And that was really the beginning of my interest in public health and inequities. And really the marriage of medicine and public health. That had a deep and long-lasting impression on me and really stayed with me throughout my career. That early experience, I think it propelled me into medicine and to medical school and also to marry medicine and public health. Dr. Pat Loehrer: Tell me a little bit, Deb, about your parents. Dr. Deborah Schrag: Sure! My mother was born in the United States. She was a teacher who many years later after having three children went to law school and she became a litigator. And actually, her boss was Rudolph Giuliani. My father is a child of World War II. He was a child of German Jewish parents who had to flee the Nazis. Probably the most interesting story is that my paternal grandfather was an OB-GYN. So, I am a fifth-generation physician. My paternal grandfather was an OB-GYN at Charité, which is a very famous Hospital in Berlin. He was the head of OB-GYN there in the 1930s. But he had, I think he was half Jewish, and the Gestapo asked him to leave and he had to leave. He was an expert in version, which is essentially flipping babies and the setting of placenta previa. He then left for Lebanon, where he was in the French Resistance and had a thriving OB-GYN practice in Beirut, Lebanon, during World War II. And at night, there was a curfew, and he was part of the resistance and passed secrets around from the Russians to the French, so very dramatic. My father was born in this setting, and arrived as a new immigrant to the United States in the 1940s, where it was very hard to be a child whose parents had a German accent, given the prejudice against Germans at that time, but also went to New York City public schools, had a tremendous opportunity. It's really kind of the classic New York immigrant success story. You know, arrived in the United States with the shirts on their back and managed to work their way to a better life and achieve success and good education through public education for all their offspring. I will also say that my father had a public health stint. He worked in North Carolina as an alternative to going and serving in the Vietnam War, he was in the Public Health Service. And he worked in North Carolina in the textile mills and worked on a disease called byssinosis, which is also known as the brown lung. It's an occupational health disease that affects textile mill workers. As a child, I spent many dinners, hearing about byssinosis and brown lung, and black lung. I think at an early age I really came to understand how the world wasn't fair, and how it was instilled in me early on that it was important to work to try to make things better, particularly for people who didn't have privilege. And I think when you come from an immigrant family, and you realize how much privilege has been bestowed on you, that really leaves an indelible mark. I have to say, as Chair of Medicine at MSK, it is staggering to me the proportion of faculty here at MSK, but also at Dana-Farber, where I worked previously, we have lots and lots of immigrants who've been able to accomplish just amazing things through just motivation and drive and energy and creativity. And so, I'm a big believer in how much immigrants have powered this country. Dr. Pat Loehrer: Deborah, are your parents still alive? Dr. Deborah Schrag: My parents are still alive. They're both in their early 80s. And they both still live on the Upper West Side of Manhattan. So, I'm very privileged and fortunate to have living parents. Dr. Pat Loehrer: I can imagine the pride that they have for you. Dr. David Johnson: I just want to jump in and let our listeners know that Deb mentioned Charité in Berlin. That's the home of multiple Nobel laureates that all of us would know like Ernst Chain, who was one of the individuals involved in the development of penicillin, but Paul Ehrlich, Robert Koch, Hans Krebs, and for cancer doctors, Otto Warburg, among others. So, it truly is a world-renowned institution. Dr. Deborah Schrag: Well, my paternal grandfather was famous for this technique called version, which essentially involves putting your stethoscope next to the uterus, figuring out where the placenta was, and then essentially trying to flip the baby without disrupting the placenta or causing any harm, which required incredible skills with a stethoscope because you had to appreciate, I guess, the placental vessels. I'm not aware that this skill is still in existence, it was an important skill to have in the 1930s. When, if you did a C-section, there was a high probability of endometritis. So, you could save the baby, but you would often lose mom to endometritis. Or you could save mom, but you might not save the baby. So, at that time it was a big deal, but thankfully no longer. Dr. David Johnson: This is why we call it an Oncology, Etc. Our listeners didn't know that we're gonna get OB information in this particular podcast. Dr. Deborah Schrag: Or a digression on the history of medicine. I do find that, you know, I am inspired by the generations that came before me. I think it's also true that there are many physicians who are first-generation physicians in their families and some of us are privileged to have lots of healthcare professionals and sort of feel it as a calling. Dr. David Johnson: I think of you with many, many talents. But one of the things that I think stood out to me is, many years ago, you were in the van, talking about the financial cost of health care. I remember a very influential paper you wrote in the New England Journal, talking about the cost of treating GI cancer, colon cancer in particular. But where did your interest in that particular aspect of health care begin? What was the stimulus there? I mean, obviously you had a lot of stimulus from your family. What else? Dr. Deborah Schrag: That's really interesting. This is a little bit of a history of oncology. At that time, I was an assistant professor and assistant attending in the GI oncology service, seeing lots of patients with colorectal cancer. And we were working on a clinical trial of a drug called ImClone C225. And that was the name of the protocol. And we were putting patients in that clinical trial. And you know what? This drug was working. We were getting excited and the drug was moving ahead. We looked at the Phase 1 data and we launched Phase 2. We had meetings with the research protocol nurse and the research assistants, team meetings, and I would say there were about 50 people who were aware between the GI oncologists and the nurses and all the research assistants. You guys know that it takes a village and even though the villages were smaller then and it wasn't a particularly large trial, there are many, many people involved and everyone had the sense that this drug might be working. Just for context for our younger listeners, this is back in the early aughts, and basically, the drug that we had to treat colorectal cancer was 5-FU in many different formats and Irinotecan. And that was it. Some people thought mitomycin might work a little bit, but it was so horrible that it really barely worked. But that was what we had in our bag of tricks. So, the fact that we had this ImClone drug that eventually came to be known as Cetuximab, was remarkable. So, here's what happened. It turned out that this is the drug made by the company ImClone. And there were some shenanigans, some insider trading. And one of the people caught up in insider trading, in addition to some people involved with the company itself was none other than Martha Stewart, sort of the famous homemaker who still publishes magazines to this day. And you may know that she actually did some time in federal prison as a result of insider trading on this drug. I remember being a junior attending, and all the people involved in the trial and all the cancer professionals, we all knew this was working. But everyone respected the confidentiality of the situation, of the patients, and all the integrity that goes into academic medicine. And I remain inspired by the integrity of all the professionals, the doctors, the residents. These were not affluent people. I can tell you. we were not paying research assistants a whole hunk of money. They investigated every trade made by this company. There were absolutely no shenanigans or improprieties from the hard-working folks who helped bring this drug to market. So, as this was going on, we had many patients who were not eligible for the trial who were interested in getting the trial. So, of course, we followed as this drug got FDA approved and came to market. You could check me but I believe it was February 2004, it was FDA approved. It came out with a huge price tag. It was approximately $10,000 per month. I was mad because I was taking care of regular New Yorkers at that point. I had public school teachers, I had patients on Medicare and they couldn't afford the 20% copay. Because $10,000 a month for Cetuximab, if you have a 20% copay and you're New York City, public school cafeteria worker, is not yet eligible for Medicare with a typical plan that a New York City public school system employee would have, that was $2,000 a month. And that did not work for one of my patients who is essentially what we used to call a lunch lady. I was so mad that I decided to channel that anger into writing what I think is a perspective for the New England Journal called, “The Price Tag on Progress”. I wrote that piece. I know that many, many people and many of my esteemed colleagues have continued to work in that area and do research on the economics of drug pricing and there are many, many experts. I didn't stick with that. Not that it's not interesting, and not that it's not important. It's incredibly interesting and important, but I felt that the solution needed to happen in the legislature, state legislature, federal legislature. I think that this is about social policies, and we need to advocate for appropriate health insurance programs to make it possible for people to get coverage when they have catastrophic illnesses, and we need to think about the entire approach to drug pricing in this country. I still think that's important. I'm not convinced that what we need is more research on the topic. I think we need more policymaking and laws on the topic. I think we're still dealing with this. I'm sad to say that it's been nearly 20 years since I wrote that perspective. But I think it was motivated by frustration, not being able to get my patient what she needed, and many patients thereafter. And just the incongruity between some people benefiting from insider trading and all the good people who were doing the right thing. Dr. Pat Loehrer: I just want to throw in one thing if I can. Len Saltz, who's one of your partners, it was a piece of that trial that he presented at ASCO talking about ImClone C225. And ironically, it had a 22.5% response rate. And Len said, it's a bummer that ImClone didn't call it C995. Dr. Deborah Schrag: You have no idea how often we used to talk about that, joke about that in the clinic. I have another good story about that drug, which I think really illustrates something I believe and I think it's actually something that Osler said but it's also something I have to say I learned from both of you. And it has to do with listening to your patient. So, I had a patient named Matthew, who was a young man, 34 years old. He walked into my clinic with a diagnosis of diffuse metastatic colorectal cancer with multiple bilateral pulmonary metastases, which came to light when his tennis game was off. He was, at that time, an early employee of a newly started company called Google. And he was working on advertising algorithms, and Matt got the drug Cetuximab. And unfortunately, he was on it for quite some time. He was on it for about five or six months. But eventually, it was pretty clear that we were coming to the end of the road. And he and his wife planned a vacation. This was part of his end-of-life process planning. It was their fifth wedding anniversary in the Berkshires. We worked so hard to get Matt to the Berkshires to a beautiful inn, and on Saturday night, my pager goes off, and Matt cannot sit up. He's weak. And he'd been complaining of terrible fatigue for weeks, to me, and I really hadn't quite figured out why Matt was so fatigued. I mean, I just didn't understand it. And we get into this inn and I get a call from the Berkshire Medical Center, a small community hospital, 'Dr. Schrag, your patient is here. He's so weak and he can't sit up.' 'What's going on?' The ER doctor says, 'Well, he has a Chvostek sign', which is a sign of severe hypocalcemia. 'So, call me back with the calcium.' The calcium is low. Well, I think those of your listeners who are closer to medical school know that when the calcium is low, you have to check the mag. And Matt's magnesium was 0.2. And he got some magnesium in the Berkshire Medical Center. And all of a sudden, he felt great. He was able to go on and enjoy the second half of his fifth anniversary weekend at the Berkshire Inn and he came back. And I felt terrible because he'd been complaining to me of fatigue for six weeks and I hadn't checked his magnesium. I was like, 50 bilateral pulmonary metastases on chemotherapy. That's a fatigue explanation. Suffice it to say that we went on to start checking magnesium on everyone getting Cetuximab. Now mind you, the drug is FDA approved and FDA labeled at this point. So, we started checking magnesium, and we find that it was low. I start getting on the phone and calling my mentors. I called Dr. Bob Mayer, who was the head of my fellowship director and was like a revered mentor to me. 'Hey, Bob, does anyone up there in Boston have low magnesium from Cetuximab?' 'We don't check magnesium.' I said, 'But can you check?' I started calling around and that's a great example of the community of oncology. We are a community. I just started working the phones and calling friends and saying 'You guys checking magnesium for any of these folks on Cetuximab?' Suffice it to say, we figured out that their EGFR receptors in the ascending loop of Henle - so, again, back to biology and pathophysiology - the drug Cetuximab was blocking reabsorption of magnesium in the kidney, and it was Cetuximab that caused a terrible magnesium wasting. Oral magnesium did not work. You had to give it intravenously, repeatedly. And we helped eliminate fatigue for a bunch of patients. About six months later, I showed up at ASCO with these little cardboard slides and a little poster back in the corner and put up our little case series, very little. But I'm proud to say that we changed the label of Cetuximab and it's now on the label that it causes hypomagnesemia. It might be one of my more cited papers, paradoxically. But I think it's a principle that really has stuck with me, and I've tried to impart it to all the students and residents and fellows, 'Listen to your patients because - I think it comes from Osler- they're telling you something. We have to pay attention.' Again, I have never forgotten that. But really listening and trying to figure out how we can use our understanding of pathophysiology and what our patients tell us to ask questions and not just accept dogma and try to figure out what we can do. And you know, I couldn't have figured that out on my own. I happened to find a really smart nephrologist who happened to be able to sort of go to animal models and knew the right studies and the right people to talk to. Dr. David Johnson: It's one of the reasons why we are a multidisciplinary specialty. And we use the expertise of our colleagues. I think that's such a wonderful example of listening to one's patient and it really profoundly impacted our understanding of how that drug works and renal physiology, actually. That wraps up part one of our interview with Dr. Deborah Schrag, Chair of Medicine at Memorial Sloan Kettering Cancer Center. We hope you've enjoyed learning about her background and her early career. In part two of our conversation, Dr. Schrag will discuss her programmatic goals at Memorial Sloan Kettering, the importance of mentorship and leadership, and what it means to have joy in the profession of medicine, and, frankly, much more. So, please be sure to join us. As always, we want to thank you for tuning in to Oncology, Etc. an ASCO educational podcast, where we will talk about just about anything and everything. So, if you have an idea for our topic or a guest, please email us at education@asco.org. Unknown Speaker: Thank you for listening to the ASCO Education Podcast. To stay up to date with the latest episodes, please click subscribe. Let us know what you think by leaving a review. For more information, visit the comprehensive education center at education.asco.org. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.
Zachary Schrag is the author of four books. He was the editor of Washington History and guest editor for the Journal of Policy History. Zachary has received many grants and fellowships. He is currently a professor of history at George Mason University, a member of the editorial board of the Journal of Urban History, and a member of the board of the Urban History Association. You can connect with Zachary on Twitter @zacharyschrag. Key points include: 03:40: How he became a professor 11:39: The Fires of Philadelphia, and the Princeton Guide to Historical Research 16:53: Two different anti-immigrant movements 24:14: Compiling data and the writing process
Es soll wohl wieder gehen: das Reisen. Nach zwei Jahren voller Einschränkungen ist zu Ostern auf einmal alles möglich: Urlaub in Deutschland sowieso, aber auch Reisen in den Rest von Europa und nach ganz weit weg sind drin - bei entsprechendem Geldbeutel. Hat euch das Fernweh denn schon gepackt? Und packt ihr jetzt die Koffer und Rucksäcke? Christoph Schrag möchte im Blue Moon von euch wissen, wohin ihr als nächstes reisen wollt. An Ostern oder später in diesem Jahr. Verbunden mit dem Reisen ist natürlich auch der Gedanke des klimafreundlichen Urlaubs. Achtet ihr darauf, wie und womit ihr verreist? Oder verzichtet sogar auf gewisse Regionen? Erzählt von euren Plänen, Zielen und... Verkehrsmitteln.
Viele der Corona-Regelungen sind seit dem Wochenende Geschichte. Keine Kontrollen mehr am Eingang von Restaurants, Clubs oder der Arbeit. Die Masken braucht ihr fast nur noch in Bus und Bahn oder beim Arzt. Auch die Tests verlangt kaum einer mehr, mit Ausnahme etwa von Schul- oder Gesundheitseinrichtungen. Trotzdem tragen viele die Maske freiwillig weiter. Die Hälfte der Einzelhändler wünscht sich sogar die Pflicht zurück. Und die Landespolitik ist unzufrieden, dass die Bundesregierung die nationalen Schutzmaßnahmen abstellt und ihnen die Verantwortung zurückgibt. Wo stehen wir? Am Ende der Pandemie oder noch mittendrin? Ist das die lang ersehnte und verdiente Rückkehr zur Normalität oder das Vorspiel zu einer neuen Eskalation der Lage? Wie geht's euch mit dem Wegfall der Regelungen oder macht ihr euch Sorgen? Christoph Schrag will von euch wissen: Wie haltet ihr es jetzt mit dem Schutz vor Corona?
For the fourth episode of Drafting the Past, I talked to historian Zachary Schrag. Dr. Schrag is a professor of history at George Mason University. He is the author of three books of history: The Fires of Philadelphia: Citizen-Soldiers, Nativists, and the 1844 Riots Over the Soul of a Nation, (Pegasus, 2021), Ethical Imperialism: Institutional Review Boards and the Social Sciences, 1965-2009 (JHU Press, 2010), and The Great Society Subway: A History of the Washington Metro (JHU Press, 2006). He is also the author of the tremendously helpful Princeton Guide to Historical Research (Princeton, 2021), a book I wish someone had handed me on the first day of graduate school. Listen to hear more about how Schrag organizes his notes, how he uses a working document, and his (and my!) love for Scrivener.
Der Angriffskrieg Russlands gegen die Ukraine hat die Welt verändert. Auch hier in Deutschland gelten neue Regeln. Russland wird isoliert. Stattdessen wenden wir uns Ländern wie Katar zu in Sachen Energie. Die Regierung hat Militär-Ausgaben in einer Höhe beschlossen, die vorher nicht denkbar war. Und im Alltag: Preise steigen stark an infolge des Krieges. Aber die Hilfsbereitschaft der Deutschen ebenfalls. Wie steht ihr zu all dem? Welche Schritte findet ihr richtig? Was fehlt euch? Ist es bemerkenswert, wie hier und heute Geflüchteten geholfen wird oder einfach selbstverständlich? Was wird, wenn der Krieg kein Ende nimmt? Wird sich dann das positive Bild der Ukraine irgendwann verändern? Hendrik Schröder und Christoph Schrag wollen mit euch über all diese und weitere Fragen zum Krieg und den Auswirkungen auf uns hier in Deutschland sprechen.
America is in a state of deep unrest, grappling with xenophobia, racial, and ethnic tension a national scale that feels singular to our time. But it also echoes the earliest anti-immigrant sentiments of the country. In 1844, Philadelphia was set aflame by a group of Protestant ideologues—avowed nativists—who were seeking social and political power rallied by charisma and fear of the immigrant menace.For these men, it was Irish Catholics they claimed would upend morality and murder their neighbors, steal their jobs, and overturn democracy. The nativists burned Catholic churches, chased and beat people through the streets, and exchanged shots with a militia seeking to reinstate order.In the aftermath, the public debated both the militia's use of force and the actions of the mob. Some of the most prominent nativists continued their rise to political power for a time, even reaching Congress, but they did not attempt to stoke mob violence again.Today, in an America beset by polarization and riven over questions of identity and law enforcement, the 1844 Philadelphia Riots and the circumstances that caused them demand new investigation.At a time many envision America in flames, The Fires of Philadelphia shows us a city—one that embodies the founding of our country—that descended into open warfare and found its way out again.-Zachary M. Schrag is the author of The Great Society Subway: A History of the Washington Metro; Ethical Imperialism: Institutional Review Boards and the Social Sciences and The Princeton Guide to Historical Research.He has received grants and fellowships from the National Science Foundation, the Gerald Ford Foundation, and the Library of Congress and has been awarded the Society for American City and Regional Planning History's John Reps Prize. He is the director of the Masters Program in History at George Mason University.
Find more stories regarding the IFB movement by visiting:– preacherboysdoc.com– https://www.facebook.com/preacherboysdoc/– https://twitter.com/preacherboysdoc– https://www.instagram.com/preacherboysdoc/To connect with a community who share the Preacher Boys Podcast mission to expose abuse in the IFB, join the OFFICIAL Preacher Boys Facebook Group: https://www.facebook.com/groups/1403898676438188/Support the Show:https://www.patreon.com/preacherboysSupport this podcast at — https://redcircle.com/preacher-boys-podcast/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
Loren and Alli Schrag are the founders and owners of Good Bull Outdoors. This popular platform is a place for insanely good wildlife photography, hunting, and conservation. In this episode, we talk about hunting the west from elk, deer, wolves, and bear. We also discuss wildlife photography, how to capture a great picture, ballot box wildlife management, wolves, and current affairs in the hunting space. Loren and Alli are inspiring, motivating, and willing to teach others about their passion for the outdoors. You will like them as much as I did! Check out Good Bull Outdoors here!! Save some money with The Western Huntsman! SKRE, Extreme Mountain Gear: promo code "Thewesternhuntsman" 15% off and free shipping! Hoffman Boots: promo code "HUNTSMAN10" for 10% off! Phelps Game Calls: promo code "Huntsman10" for 10% off! Follow The Western Huntsman on Social! jim@thewesternhuntsman.com
© 2020-2025 Ivy Podcast Discovery LLC
